Novartis trial win lifts profile of new breast cancer drug

Novartis’s efforts to tackle an elusive gene mutation behind tough-to-treat breast cancer were rewarded on Thursday, as the Swiss drugmaker said one of its investigational medicines slowed disease progression.

nalysts said the drug, called BYL719, is on a trajectory to take a leading role in advanced breast cancer treatment.

Novartis said its drug combined with hormone therapy improved progression-free survival in breast cancer patients whose tumors had hormone receptors but not so-called HER2 proteins.

To read the full article, click HERE

REUTERS/Arnd Wiegmann/File Photo